What Does the Research Say About Tysabri and PML?
From General Health Science to Targeted Risk Communication
If you or someone you care about is taking Tysabri, you may be concerned about the risk of progressive multifocal leukoencephalopathy (PML). The research record offers important insights but also leaves some questions unanswered. This page reviews the published evidence on Tysabri and PML, highlighting both established findings and areas of uncertainty.
Clinical Presentation and Diagnosis of PML
PML is an opportunistic viral infection of the brain caused by the JC virus, typically occurring only in immunocompromised individuals. The condition usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Clinical presentation often includes progressive neurological deficits such as weakness, cognitive decline, visual disturbances, and coordination problems. Diagnosis relies on brain MRI findings and detection of JC virus DNA in cerebrospinal fluid. Healthcare professionals are advised to monitor patients on Tysabri for any new sign or symptom suggestive of PML and to withhold Tysabri immediately at the first such sign (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Importantly, PML has been reported even after discontinuation of Tysabri in patients who did not have findings suggestive of PML at the time of stopping treatment; therefore, monitoring should continue for at least six months following discontinuation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Tysabri Pharmacology and Reported Adverse Effects
Tysabri is a monoclonal antibody that binds to alpha-4 integrins, inhibiting leukocyte adhesion and migration into inflamed tissues. It is indicated as monotherapy for relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). In Crohn's disease, Tysabri should not be used in combination with immunosuppressants or TNF-alpha inhibitors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The most serious adverse effect is PML, which is highlighted in a boxed warning. Additional adverse effects include bleeding abnormalities and thrombocytopenia; Tysabri should be discontinued in patients with thrombocytopenia, and neonatal thrombocytopenia and anemia have occurred in exposed neonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Mechanistic Pathways Linking Tysabri to PML
The mechanism by which Tysabri increases PML risk involves impaired immune surveillance of the central nervous system. By blocking leukocyte trafficking, Tysabri reduces the ability of the immune system to control JC virus reactivation. Three established risk factors for PML in Tysabri-treated patients are: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating and continuing treatment, weighing expected benefit against PML risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of this risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Adequacy of Warnings
The prescribing information for Tysabri includes a boxed warning that clearly states the increased risk of PML, which usually leads to death or severe disability. The warning specifies risk factors and instructs healthcare professionals to monitor patients and withhold Tysabri at the first sign of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these warnings, questions may arise regarding whether patients and providers were adequately informed about the magnitude and latency of risk, particularly in the context of long-term therapy. The boxed warning also notes that PML has occurred after discontinuation, which may affect the adequacy of post-treatment monitoring advice.
Settlement-Related Considerations for Affected Patients
For patients in Massachusetts who have developed PML after Tysabri use, settlement considerations involve the statute of limitations for filing claims. In Massachusetts, the statute of limitations for personal injury claims generally is three years from the date the injury is discovered or reasonably should have been discovered. Given that PML symptoms may develop insidiously and diagnosis can be delayed, the timeline between exposure and documented harm is critical. The boxed warning indicates that PML risk increases with longer treatment duration, especially beyond two years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients should document the date of first Tysabri infusion, duration of therapy, and date of PML diagnosis. Additionally, because PML can occur after discontinuation, the date of last exposure may not align with symptom onset. Legal counsel should be sought to determine whether the statute of limitations has been met, considering the discovery rule.
Timeline Between Exposure and Documented Harm
The latency between Tysabri initiation and PML diagnosis varies. The boxed warning identifies longer treatment duration, especially beyond two years, as a risk factor (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, PML has been reported in patients with shorter exposure, and cases have occurred after discontinuation. This variability underscores the importance of early MRI and clinical monitoring. For settlement purposes, establishing a clear timeline from first exposure to diagnosis is essential to demonstrate causation and meet filing deadlines.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is the statute of limitations for Tysabri PML claims in Massachusetts?
In Massachusetts, the statute of limitations for personal injury claims generally is three years from the date the injury is discovered or reasonably should have been discovered. For Tysabri-associated PML, this means the clock starts when the patient knew or should have known that their PML was caused by Tysabri. Given the insidious onset of PML, it is crucial to document the date of diagnosis and the date of first Tysabri exposure. Legal counsel should be consulted to determine if the filing deadline has been met.
Can PML occur after stopping Tysabri?
Yes, PML has been reported even after discontinuation of Tysabri in patients who did not have findings suggestive of PML at the time of stopping treatment. Therefore, monitoring should continue for at least six months following discontinuation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This post-discontinuation risk is important for settlement timelines, as the date of last exposure may not align with symptom onset.
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
Related Articles
References
Request a Free Case Review
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.